TP53 and cancer: Given that cancers show aberrant splicing of thousands of transcripts (73) that associate with tumour biology and therapeutic response (74), the clinical associations of TP53 isoform mRNA changes are equally compatible with isoforms representing a non-specific marker of global splicing aberration rates in a tumour, rather than indicating a functional effect of the particular TP53 isoform.